Actuate Therapeutics (ACTU) News Today $7.49 -0.28 (-3.60%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$7.46 -0.03 (-0.33%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 17 at 2:07 AM | tmcnet.comActuate Therapeutics to be included in Russell 3000, Russell 2000 indexesJune 16 at 9:16 AM | seekingalpha.comActuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 16 at 8:30 AM | globenewswire.comActuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic CancerJune 4, 2025 | seekingalpha.comActuate Therapeutics shares highlights from KOL eventon elraglusib dataJune 3, 2025 | finance.yahoo.comActuate Therapeutics (NASDAQ:ACTU) Given New $20.00 Price Target at HC WainwrightHC Wainwright upped their price objective on Actuate Therapeutics to $20.00 and gave the company a "buy" rating in a research note on Tuesday.June 3, 2025 | marketbeat.com2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than DoubleJune 2, 2025 | msn.comActuate Therapeutics Reports Positive Phase 2 Trial Results for Elraglusib in Metastatic Pancreatic Cancer, Improving Overall SurvivalJune 2, 2025 | nasdaq.comActuate Therapeutics' Shares Gain on Positive Phase 2 Trial for Pancreatic Cancer TreatmentJune 2, 2025 | marketwatch.comActuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancerJune 1, 2025 | msn.comActuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic CancerMay 31, 2025 | insidermonkey.comActuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: ...May 31, 2025 | gurufocus.comActuate Therapeutics (ACTU) Cancer Drug Shows Promise in Phase 2 TrialMay 31, 2025 | gurufocus.comActuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment oMay 31, 2025 | investing.comActuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic CancerMay 31, 2025 | globenewswire.comActuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic CancerMay 22, 2025 | globenewswire.comBIOS Capital Management LP Takes $78.75 Million Position in Actuate Therapeutics (NASDAQ:ACTU)BIOS Capital Management LP bought a new stake in Actuate Therapeutics (NASDAQ:ACTU - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 9,893,651 shares of the company's stock, valued atMay 22, 2025 | marketbeat.comBlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice PresidentMay 9, 2025 | finance.yahoo.comActuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic CancerMay 8, 2025 | nasdaq.comActuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic CancerMay 8, 2025 | seekingalpha.comActuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 ...May 6, 2025 | gurufocus.comActuate Therapeutics Announces Positive Phase 2 Trial ResultsMay 6, 2025 | tipranks.comActuate Therapeutics to Participate in Citizens Life Sciences Conference 2025April 30, 2025 | gurufocus.comCraig-Hallum bullish on Actuate Therapeutics, initiates with a BuyApril 24, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU)April 24, 2025 | markets.businessinsider.comCraig Hallum Begins Coverage on Actuate Therapeutics (NASDAQ:ACTU)Craig Hallum began coverage on shares of Actuate Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $21.00 target price for the company.April 24, 2025 | marketbeat.comActuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.com55,246 Shares in Actuate Therapeutics (NASDAQ:ACTU) Acquired by Voss Capital LPVoss Capital LP acquired a new stake in shares of Actuate Therapeutics (NASDAQ:ACTU - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 55,246 shares of the company's stock, valued at approximApril 23, 2025 | marketbeat.comActuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025April 17, 2025 | globenewswire.comActuate Therapeutics (NASDAQ:ACTU) Trading 6% Higher - Still a Buy?Actuate Therapeutics (NASDAQ:ACTU) Stock Price Up 6% - What's Next?April 12, 2025 | marketbeat.comActuate Therapeutics files to sell 3.9M shares of common stock for holdersMarch 29, 2025 | markets.businessinsider.comActuate Therapeutics: Looking To Make An Impact In Pancreatic CancerMarch 26, 2025 | seekingalpha.comWhat is HC Wainwright's Forecast for ACTU Q1 Earnings?Actuate Therapeutics (NASDAQ:ACTU - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Actuate Therapeutics in a report issued on Monday, March 17th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.26) forMarch 20, 2025 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Now Covered by HC WainwrightHC Wainwright began coverage on shares of Actuate Therapeutics in a research report on Monday. They issued a "buy" rating and a $20.00 price objective on the stock.March 18, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy RecommendationMarch 18, 2025 | msn.comActuate Therapeutics initiated with a Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comActuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic CancerMarch 17, 2025 | tipranks.comActuate Therapeutics (NASDAQ:ACTU) Shares Up 4.5% - Here's What HappenedActuate Therapeutics (NASDAQ:ACTU) Trading 4.5% Higher - Time to Buy?March 2, 2025 | marketbeat.comCandel Therapeutics stock drops despite OS improvement in PDAC trialFebruary 27, 2025 | msn.comActuate Therapeutics completes enrollment in Phase 2 trial of elraglusibFebruary 25, 2025 | msn.comIs Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?February 12, 2025 | finance.yahoo.comActuate Therapeutics sets annual meeting for May 22February 8, 2025 | msn.comActuate Therapeutics to Participate in Upcoming Investor Conferences in FebruaryFebruary 6, 2025 | globenewswire.comActuate Therapeutics' (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10thActuate Therapeutics' (NASDAQ:ACTU - Get Free Report) lock-up period will expire on Monday, February 10th. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.February 3, 2025 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Stock Price Down 5.4% - What's Next?Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 5.4% - Should You Sell?January 30, 2025 | marketbeat.comEMA gives OMPD to Actuate’s pancreatic cancer therapyJanuary 8, 2025 | msn.comActuate Therapeutics announces EMA granted OMPD to elraglusibJanuary 8, 2025 | markets.businessinsider.comActuate Therapeutics (NASDAQ:ACTU) Shares Down 2.1% - Time to Sell?Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.1% - Should You Sell?January 8, 2025 | marketbeat.comActuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic CancerJanuary 7, 2025 | markets.businessinsider.comActuate Therapeutics announces interim Phase 2 data of elraglusibDecember 18, 2024 | markets.businessinsider.com Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address ACTU Media Mentions By Week ACTU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACTU News Sentiment▼0.000.57▲Average Medical News Sentiment ACTU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACTU Articles This Week▼31▲ACTU Articles Average Week Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KALV News Today XNCR News Today EOLS News Today STOK News Today SION News Today NUVB News Today CDXC News Today UPB News Today DNTH News Today MAZE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACTU) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACTU Stock Free ACTU Stock Alerts